PubMed | Tianjin University of Technology and Tasly Holding Group Co.
Type: | Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences | Year: 2017
It is often challenging to precisely manipulate the release behavior of hydrophilic drugs that is believed to be crucial for a satisfactory therapeutic outcome. The aim of this work was to regulate the dissolution of hydrophilic drug from hot-melt extruded solid dispersion via rational screening of the pore-forming agents. Venlafaxine hydrochloride and Compritol 888 ATO was selected as the model drug and carrier excipient, respectively. Hydrophilic polyethylene glycol (PEG 6000) and polyvinylpyrolidone (PVP K30) were chosen as the transient pore-forming agents. The X-ray diffraction and thermal analysis showed that both drug and carrier existed in the crystalline form. Both types of polymers could generate pores upon dissolution test and the drug release rate was proportionally correlated to the pore-forming agent content. The mathematical modelling showed that the Ritger-Peppas model gave the best fit to the release curves, which demonstrates a diffusion-dominant release mechanism. The scanning electron microscopy and mercury intrusion porosimetry analysis proved that PVP K30 could generate large pores with low porosity, but PEG 6000 produced smaller pores with relatively high porosity. The in vivo pharmacokinetics study in rat revealed that solid dispersions containing either PEG 6000 or PVP K30 (both at 2.5%, w/w) exhibited an elevated bioavailability compared to the commercial product, Effexor XR. The current work implied that rational screening of transient pore-forming polymer in solid dispersion could be a robust approach for controlling hydrophilic drug release.
Zhang H.,Northwest University, China |
Zhang H.,Zhejiang Sci-Tech University |
Jin W.,Zhejiang Sci-Tech University |
Zhu X.,Northwest University, China |
And 8 more authors.
PLoS ONE | Year: 2016
Replanting disease is a major factor limiting the artificial cultivation of the traditional Chinese medicinal herb Salvia miltiorrhiza. At present, little information is available regarding the role of miRNAs in response to replanting disease. In this study, two small RNA libraries obtained from first-year (FPR) and second-year plant (SPR) roots were subjected to a high-throughput sequencing method. Bioinformatics analysis revealed that 110 known and 7 novel miRNAs were annotated in the roots of S. miltiorrhiza. Moreover, 39 known and 2 novel miRNAs were identified and validated for differential expression in FPR compared with SPR. Thirty-one of these miRNAs were further analyzed by qRT-PCR, which revealed that 5 miRNAs negatively regulated the expression levels of 7 target genes involved in root development or stress responses. This study not only provides novel insights into the miRNA content of S. miltiorrhiza in response to replanting disease but also demonstrates that 5 miRNAs may be involved in these responses. Interactions among the differentially expressed miRNAs with their targets may form an important component of the molecular basis of replanting disease in S. miltiorrhiza. © 2016 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Xing B.,Zhejiang Sci-Tech University |
Yang D.,Zhejiang Sci-Tech University |
Guo W.,Zhejiang Sci-Tech University |
Liang Z.,Zhejiang Sci-Tech University |
And 3 more authors.
Molecules | Year: 2015
Phenolic acids and tanshinones are two groups of bioactive ingredients in Salvia miltiorrhiza Bunge. As a heavy metal elicitor, it has been reported that Ag+ can induce accumulations of both phenolic acids and tanshinones in S. miltiorrhiza hairy roots. In this study, the effects of Ag+ treatment on accumulations of six phenolic acids and four tanshinones in S. miltiorrhiza hairy roots were investigated. To further elucidate the molecular mechanism, expressions of key genes involved in the biosynthesis of these ingredients were also detected. The results showed that although the total phenolic acids content was almost not affected by Ag+ , accumulations of rosmarinic acid (RA), caffeic acid and ferulic acid were significantly increased, while accumulations of salvianolic acid B (LAB), danshensu (DSU) and cinnamic acid were decreased. We speculate that LAB probably derived from the branch pathway of DSU biosynthesis. Contents of four tanshinones were enhanced by Ag+ and their accumulations were more sensitive to Ag+ than phenolic acids. Genes in the upstream biosynthetic pathways of these ingredients responded to Ag+ earlier than those in the downstream biosynthetic pathways. Ag+ probably induced the whole pathways, upregulated gene expressions from the upstream pathways to the downstream pathways, and finally resulted in the enhancement of ingredient production. Compared with phenolic acids, tanshinone production was more sensitive to Ag+ treatments. This study will help us understand how secondary metabolism in S. miltiorrhiza responds to elicitors and provide a reference for the improvement of the production of targeted compounds in the near future. © 2014 by the authors licensee MDPI Basel Switzerland.
Han M.,Tasly Holding Group Co. |
Han M.,Tianjin Medical University |
Wang G.-C.,Tasly Holding Group Co. |
Duan H.-Q.,Tianjin Medical University
Chinese Chemical Letters | Year: 2014
The self-assembly of cationic perylene diimide (PDI) and anionic cholesterol derivatives (CHOL) was conveniently achieved by the electrostatic attraction and π-π stacking interactions, exhibiting the well-defined supramolecular nanofibers ranging from hundreds of nanometers to micron dimension. © 2013 Guo-Cheng Wang and Hong-Quan Duan.
Yan J.-W.,China Pharmaceutical University |
Yan J.-W.,Tasly Holding Group Co. |
Zhong J.,Tasly Holding Group Co. |
Wang G.-C.,Tasly Holding Group Co. |
Feng F.,China Pharmaceutical University
Chinese Journal of New Drugs | Year: 2014
Tumor genesis, development and metastasis are closely related to cancer glycolysis. The metabolic enzymes in cancer glycolysis pathway have become important targets for oncotherapy. This review mainly summarized the mechanism of tumor metabolic enzymes in cancer glycolysis and inhibitors of these enzymes reported in recent years.
Tasly Holding Group Co. | Date: 2016-09-23
The invention relates to a preparation of taxanes for intravenous administration consisting of a drug solution and an emulsion. The drug solution consists of paclitaxel or docetaxel, a pH regulator and an organic solvent for injection. The emulsion includes a fat emulsion and is composed of oil for injection, an emulsifier, an antioxidant, an isotonic regulator, a stabilizer, a pH regulator and water for injection. When used, the drug solution at the clinical dosage can be added and evenly mixed in the emulsion to perform intravenous drip directly; or the drug solution at the clinical dosage can also be firstly added into the emulsion with no less than 5 times volume of the drug solution and then a predetermined amount of normal saline or glucose solution for injection is added to perform intravenous drip. The preparation of the present invention does not contain solubilizer.
Jin L.,Nanjing Agricultural University |
Zhao W.-S.,Tasly Pharmaceutical Group Company Ltd |
Guo Q.-S.,Nanjing Agricultural University |
Zhang W.-S.,Tasly Pharmaceutical Group Company Ltd |
And 2 more authors.
Chinese Traditional and Herbal Drugs | Year: 2015
Objective: To establish a UPLC fingerprint method of Paeoniae Alba Radix, and provide comprehensive evaluation of their quality in different regions. Methods: The UPLC chromatographic column was Acquity UPLC® HSS T3 (100 mm × 2.1 mm, 1.8 μm). The mobile phase was acetonitrile-0.05% phosphoric acid water with gradient elution. The detection wavelength was 230 nm and column temperature was 30 ℃ with the flow rate of 0.4 mL/min. Similarity analysis, hierarchical clustering analysis, and principal component analysis were undertaken to study 23 sets of UPLC fingerprints of Paeoniae Alba Radix. Results: A specific UPLC fingerprint of Paeoniae Alba Radix was established and eight common peaks were designated. The results showed that the qualities of the 23 sets of Paeoniae Alba Radix were not stable and the samples collected from same region and different regions both had certain differences. Conclusion: UPLC fingerprint is an available and convenient method which can be used to access the quality of Paeoniae Alba Radix rapidly. © 2015, Editorial Office of Chinese Traditional and Herbal Drugs. All right reserved.
PubMed | Tasly Holding Group Company and China Pharmaceutical University
Type: Comparative Study | Journal: AAPS PharmSciTech | Year: 2016
AJS is the code name of an untitled novel medicative compound synthesized by the Tasly Holding Group Company (Tianjin, China) based on the structure of cinnamamide, which is one of the Biopharmaceutics Classification System (BCS) class II drugs. The drug has better antidepressant effect, achieved by acting on the 5-hydroxytryptamine receptor. However, the therapeutic effects of the drug are compromised due to its poor water solubility and lower bioavailability. Herein, a self-microemulsifying drug delivery system (SMEDDS) was developed to improve its solubility and oral bioavailability. AJS-SMEDDS formulation was optimized in terms of drug solubility in the excipients, droplet size, stability, and drug precipitation using a pseudo-ternary diagram. The pharmacokinetic study was performed in rats, and the drug concentration in plasma samples was assayed using the high-performance liquid chromatography-electrospray tandem mass spectrometry (HPLC-MS/MS) method. The optimized formulation for SMEDDS has a composition of castor oil 24.5%, Labrasol 28.6%, Cremphor EL 40.8%, and Transcutol HP 2.7% (co-surfactant). No drug precipitation or phase separation was observed from the optimized formulation after 3 months of storing at 25C. The droplet size of microemulsion formed by the optimized formulation was 26.081.68 nm, and the zeta potential was -2.76 mV. The oral bioavailability of AJS-SMEDDS was increased by 3.4- and 35.9-fold, respectively, compared with the solid dispersion and cyclodextrin inclusion; meanwhile, the C max of AJS-SMEDDS was about 2- and 40-fold as great as the two controls, respectively. In summary, the present SMEDDS enhanced oral bioavailability of AJS and was a promising strategy to orally deliver the drug.
PubMed | Zhejiang Sci-Tech University, Tianjin Tasly Modern TCM Resources Co., Shaanxi University of Technology and Tasly Holding Group Co.
Type: Journal Article | Journal: Molecules (Basel, Switzerland) | Year: 2015
Nitric oxide (NO), a well-known signaling molecule plays an important role in abiotic and biotic stress-induced production of plant secondary metabolites. In this study, roles of NO in water stress-induced tanshinone production in Salvia miltiorrhiza hairy roots were investigated. The results showed that accumulations of four tanshinone compounds in S. miltiorrhiza hairy roots were significantly stimulated by sodium nitroprusside (SNP, a NO donor) at 100 M. Effects of SNP were just partially arrested by the mevalonate (MVA) pathway inhibitor (mevinolin), but were completely inhibited by the 2-C-methyl-d-erythritol-4-phosphate pathway (MEP) inhibitor (fosmidomycin). The increase of tanshinone accumulation and the up-regulation of HMGR and DXR expression by PEG and ABA treatments were partially inhibited by an inhibitor of NO biosynthesis (N-nitro-L-arginine methyl ester (L-NAME)) and a NO scavenger (2-(4-Carboxyphenyl)- 4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (c-PTIO)). Simultaneously, NO generation in the hairy roots was triggered by PEG and ABA, and the effects were also arrested by c-PTIO and L-NAME. These results indicated that NO signaling probably plays a central role in water stress-induced tanshinone production in S. miltiorrhiza hairy roots. SNP mainly stimulated the MEP pathway to increase tanshinone accumulation.
News Article | February 23, 2017
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a global nutrition company, today announced it has reached an agreement in principle to form a joint venture with Tasly Holding Group, a leading Traditional Chinese Medicine (TCM) health products and services corporation. The joint venture would develop and commercialize high-quality consumer health products based on Tasly’s deep portfolio of proprietary formulations, patents, know-hows, and clinical studies by leveraging the Herbalife Nutrition scientific, regulatory and commercial development expertise to bring products to a global market through the Herbalife Nutrition distributor network. The proposed joint venture furthers the Herbalife Nutrition business plan to expand its product range globally. “We are honored to work with Tasly, which is well regarded for its premium TCM products and ingredients,” said Michael O. Johnson, chairman and CEO, Herbalife. “The Herbalife Nutrition seed to feed philosophy ensures the quality and traceability of our ingredients from cultivation to the final delivery of products to customers, and Tasly has patents, clinical research, and traceability of key ingredients, making this a natural partnership.” Dr. Henry Sun, Vice-Chair of Tasly Holding Group, said, “We believe the combination of Tasly’s pharmaceutical development experience and experts, clinical research skills and network along with the two firms' high-end quality control standards, will bring the best evidence-based products to consumers.” Tasly manages a broad spectrum of leading pharmaceutical, consumer products, healthcare services and distribution channels in China. As a pioneer of TCM modernization, Tasly, through innovations in standards and technologies, has created a manufacturing and development process and set up a comprehensive, standardized and digital system which produces high-quality TCM products. The joint venture is expected to be finalized within the next 60 days. Herbalife is a global nutrition company that has been changing people's lives with great products since 1980. Our nutrition, weight-management, energy and fitness and personal care products are available exclusively to and through dedicated Herbalife Independent Members in more than 90 countries. We are committed to fighting the worldwide problems of poor nutrition and obesity by offering high-quality products, one-on-one coaching with an Herbalife Member and a community that inspires customers to live a healthy, active life. We support the Herbalife Family Foundation (HFF) and its Casa Herbalife programs to help bring good nutrition to children in need. We also sponsor more than 190 world-class athletes, teams and events around the globe, including Cristiano Ronaldo, the LA Galaxy and champions in many other sports. The company has over 8,000 employees worldwide, and its shares are traded on the New York Stock Exchange (NYSE: HLF) with net sales of $4.5 billion in 2015. The Herbalife website contains a significant amount of financial and other information about the company at http://ir.Herbalife.com. The company encourages investors to visit its website from time to time, as information is updated and new information is posted. To learn more, visit Herbalife.com or IAmHerbalife.com. Tasly Holding Group Co., Ltd. was founded in 1994 and is based in Tianjin, China. As a high-tech enterprise group, with the core of the pharmaceutical operations, Tasly's business includes Modern TCM, Chemical Medicine, Bio-pharmaceuticals, and high-quality consumer health products covering Scientific Research, Cultivation, Extraction, Formulation and Marketing. Tasly has created industrialized platform for TCM innovative development and intelligent manufacturing. Tasly has an extensive marketed product line and pipeline supported by strong patent portfolio including more than one thousand patents. The company has over 18,000 employees worldwide. The Tasly website contains a significant amount of information about the company and its products at http://www.tasly.com/en_web/. This earnings release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, such as those disclosed or incorporated by reference in our filings with the Securities and Exchange Commission. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in our forward-looking statements include, among others, the following: We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.